~~<i id='48581AEE3D'><strike id='48581AEE3D'><tt id='48581AEE3D'><pre id='48581AEE3D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：knowledge 2025-09-27 09:55:06 - browse：9

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Peter Marks talks Operation Warp Speed for Rare Diseases

entertainment

Wikipedia

hotspot

focus

AdobeYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechistransformingthelifesc

WSS

European regulators consider appeal over Amylyx ALS drug

Humana CEO Bruce Broussard to step down in 2024

Readout LOUD podcast: Merger Mondays, Ozempic panic

In 'major milestone,' FDA approves first cell therapy for solid tumors

New CMS data security rules will hurt Medicare, Medicaid research

Secretariat’s lessons for human medicine

knowledge

knowledge

entertainment

Medical records are filled with copy

Flagship Pioneering startup Sonata Therapeutics lays off 21

Medicare proposal to cover medical devices draws a mixed reaction

Humana CEO Bruce Broussard to step down in 2024

In age of alternative facts, a scholarly course on calling out crap

European regulators consider appeal over Amylyx ALS drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As AI regulations shape up, health tech startups beg for clarity

Duchenne breakthrough therapy leaves behind pioneering families

There’s no way to know how good AI health technologies are

Wikipedia

Peter Marks talks Operation Warp Speed for Rare Diseases

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Measles policy set amid Florida outbreak alarms vaccine proponents

Eight reasons why you should get an updated Covid vaccine

A new drug could help frostbite victims avoid its ravages

How should state employee insurance handle Wegovy?

Wikipedia

Wikipedia

hotspot

focus